S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:QURE

uniQure Stock Forecast, Price & News

$18.03
-0.23 (-1.26%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$18.03
$18.87
50-Day Range
$18.03
$31.08
52-Week Range
$18.03
$40.49
Volume
468,928 shs
Average Volume
497,652 shs
Market Capitalization
$833.24 million
P/E Ratio
2.65
Dividend Yield
N/A
Beta
1.01
30 days | 90 days | 365 days | Advanced Chart
Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.


uniQure logo

About uniQure

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Headlines

uniQure (NASDAQ:QURE) Hits New 1-Year Low at $18.55
January 19, 2022 |  americanbankingnews.com
uniQure: Betting On Hemophilia-B Cure - Seeking Alpha
January 18, 2022 |  seekingalpha.com
uniQure: Betting On Hemophilia-B Cure
January 18, 2022 |  seekingalpha.com
Is Uniqure NV (QURE) A Good Stock To Buy? - Yahoo Finance
January 12, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QURE
Employees
332
Year Founded
N/A

Sales & Book Value

Annual Sales
$37.51 million
Book Value
$5.48 per share

Profitability

Net Income
$-125.02 million
Pretax Margin
61.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
44,985,000
Market Cap
$833.24 million
Optionable
Optionable

Company Calendar

Last Earnings
10/24/2021
Today
1/22/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.43 out of 5 stars

Medical Sector

171st out of 1,418 stocks

Pharmaceutical Preparations Industry

69th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -












uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure
or view top-rated stocks.

How has uniQure's stock been impacted by Coronavirus (COVID-19)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 62.1% and is now trading at $18.03.
View which stocks have been most impacted by COVID-19
.

Are investors shorting uniQure?

uniQure saw a increase in short interest in December. As of December 31st, there was short interest totaling 2,870,000 shares, an increase of 22.1% from the December 15th total of 2,350,000 shares. Based on an average daily trading volume, of 592,200 shares, the days-to-cover ratio is currently 4.8 days. Currently, 7.5% of the shares of the stock are sold short.
View uniQure's Short Interest
.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for uniQure
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Sunday, October, 24th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($1.05) by $0.26. The biotechnology company earned $2 million during the quarter, compared to analyst estimates of $2.13 million. uniQure had a trailing twelve-month return on equity of 75.59% and a net margin of 64.09%. The business's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the company posted ($1.21) EPS.
View uniQure's earnings history
.

What price target have analysts set for QURE?

10 analysts have issued 1 year price targets for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they expect uniQure's share price to reach $59.31 in the next year. This suggests a possible upside of 228.9% from the stock's current price.
View analysts' price targets for uniQure
or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Nordea Investment Management AB (0.59%), Henry James International Management Inc. (0.34%), State of Alaska Department of Revenue (0.06%), Cutler Group LP (0.00%), Boenning & Scattergood Inc. (0.04%) and Future Financial Wealth Managment LLC (0.00%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure
.

Which major investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, and State of Alaska Department of Revenue. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure
or view top insider-selling stocks.

Which major investors are buying uniQure stock?

QURE stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP, Boenning & Scattergood Inc., Future Financial Wealth Managment LLC, and Henry James International Management Inc..
View insider buying and selling activity for uniQure
or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $18.03.

How much money does uniQure make?

uniQure has a market capitalization of $833.24 million and generates $37.51 million in revenue each year. The biotechnology company earns $-125.02 million in net income (profit) each year or $6.80 on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000, via email at [email protected], or via fax at 31-20-566-9272.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.